The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
These advanced tools allow researchers to screen millions of compounds from chemical databases to identify promising therapeutic candidates, significantly reducing the time and cost typically required to explore the vast chemical space.
In clinical trials, AI models enhance the selection of patient populations and help predict outcomes, leading to higher success rates for novel drug development.
However, as AI becomes more embedded in the drug discovery pipeline, regulatory bodies have stepped up efforts to ensure these technologies are integrated safely and ethically. To that end, regulators are increasingly engaging with industry stakeholders to adapt and evolve policy frameworks.
Beyond AI, cloud-based technologies are pivotal in modernizing regulatory submissions and data exchange. Cloud platforms enable real-time collaboration and offer greater flexibility in product development and lifecycle management.
Despite these advantages, cloud-based systems also raise concerns about data security and intellectual property protection. These risks have prompted regulators to develop more stringent guidelines aimed at safeguarding sensitive information.
To support evidence-based decisions, regulatory agencies are also leveraging real-world evidence (RWE). Multiple studies suggest that incorporating RWE into regulatory evaluations has improved the overall quality of decisions on new drug approvals.
Standardization is another key focus area. Broader adoption of the electronic common technical document (eCTD) format within the International Council for Harmonisation (ICH) framework is helping bring greater consistency to regulatory submissions.
Standardized documentation not only reduces duplication and minimizes errors but also provides pharmaceutical companies with a more predictable and streamlined submission process.
Reference:
Regulatory Trends in Pharma Manufacturing: Key Changes to Watch in 2025
Today we announce that Exim is rebranding as ExSyn. We are presenting a new brand identity and website as a reflection of our relentless transformation over the course of 30 years serving the pharma and chemical industries. The new brand builds upon our core strengths as a sourcing company and captures our most essential duty: helping improve people’s health and lives.
Explora el Universo del Entretenimiento: Juegos de Casino en Bet365 Si eres un apasionado de los juegos de azar, sin duda has oído hablar de bet365 juegos de casino. Esta plataforma ofrece una experiencia inigualable para los amantes del entretenimiento online, con una amplia gama de opciones que satisfacen todos los gustos. Desde las tragamonedas […]
Boo Casino: ¡Descubre el Emoción del Bono de 100 Pesos! Bienvenido a Boo Casino, el lugar donde la emoción y la diversión se unen para ofrecerte una experiencia de juego sin igual. En este artículo, conocerás todo sobre el bono de 100 pesos y cómo puedes explotar al máximo esta oferta. ¡Prepárate para vivir momentos […]
Aproveite ao Máximo o Bônus do Cassino Bet365: Estratégias para Vencer! O Bet365 Casino tem se destacado como uma das maiores plataformas de jogos online do mundo, oferecendo uma vasta gama de jogos e uma experiência de usuário inigualável. Uma das chaves para aumentar suas chances de ganhar são os bônus incríveis que a plataforma […]